Read More
CStone Pharmaceuticals (02616) announced a placement of 118 million shares after trading hours on Tuesday, representing around 7.4 percent of the company’s enlarged issued share capital.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
The gross proceeds from the placement amount to HK$1.06 billion.
The placement price is set at HK$8.97 per share, representing a 6.95 percent discount to the previous closing price of HK$9.64.
The net proceeds are estimated to be HK$1.05 billion. Of this, 90 percent will be used for further research and development of assets under the company’s Pipeline 2.0, and the remaining will be allocated to general corporate purposes where appropriate.












